Cerenis Therapeutics announced the appointment of a new chief medical officer and new board members. Dr. Renee Benghozi was appointed as new chief medical officer of the company. Appointment of new board members: Mr. Christian Chavy, CEO of Stallergenes, Dr. Michael Davidson and Dr. Marc Riviere, General Partner at the TVM Capital Life Science team join the Cerenis Board of Directors as new members.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.318 EUR | +2.33% | +3.45% | +2.33% |
06-14 | Abionyx: positive response from FDA, share price rises | CF |
06-13 | ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.33% | 44.55M | |
+15.73% | 121B | |
+18.97% | 112B | |
+4.43% | 22.57B | |
-18.80% | 20.82B | |
-14.18% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.87% | 13.17B | |
+27.32% | 11.11B |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- Cerenis Therapeutics Announces Executive Changes